Compare Illumina, Inc. (ILMN) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs ProShares UltraPro S&P500 — how do they compare? Illumina, Inc. trades at $181.14 (market cap $27.94B), while ProShares UltraPro S&P500 trades at $140.25. Which is the better fit depends on your goals.
| ILMN | UPRO | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $194.33 | $150.93 |
52-Week Low | $91.00 | $89.29 |
Enterprise Value | $29.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
UPRO trades at $138.50, down 0.4% on the day, with a bearish technical signal driven by moving averages. Key support lies at $135, while resistance is at $141. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights S&P 500 concentration risks and AI-driven market volatility, influencing this leveraged ETF's performance.
The outlook is cautious due to technical weakness and broader market concerns over valuation and tech stock reliance. Risks include market corrections and ETF-specific volatility. Investors should weigh the lack of fundamental data against the leveraged exposure to S&P 500 trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
